Zobrazeno 1 - 10
of 1 997
pro vyhledávání: '"glp-1 receptor agonist"'
Publikováno v:
Diabetes, Metabolic Syndrome and Obesity, Vol Volume 17, Pp 4817-4824 (2024)
Silvia Gentinetta,1,* Francesca Sottotetti,2,* Matteo Manuelli,3 Hellas Cena2,3 1Novo Nordisk Italia SpA, Roma, Italy; 2Laboratory of Dietetics and Clinical Nutrition, Department of Public Health, Experimental and Forensic Medicine, Universit
Externí odkaz:
https://doaj.org/article/ec456e83f71c45a596f51a20ae4a0989
Autor:
Liu M, Guo S, Li X, Tian Y, Yu Y, Tang L, Sun Q, Zhang T, Fan M, Zhang L, Xu Y, An J, Gao X, Han L
Publikováno v:
Drug Design, Development and Therapy, Vol Volume 18, Pp 3925-3938 (2024)
Mei Liu,1,* Sili Guo,1,* Xiaohan Li,1,* Yang Tian,1 Yanjie Yu,2 Lili Tang,1 Qimei Sun,1 Ting Zhang,1 Mingwei Fan,3 Lili Zhang,1 Yingjiang Xu,4 Jiajia An,5 Xiangqian Gao,6 Lei Han,7 Lei Zhang1 1Department of Endocrinology and Metabolism, B
Externí odkaz:
https://doaj.org/article/af84abfcba28471db033b5a7c80a4493
Publikováno v:
Heart India, Vol 12, Iss 2, Pp 57-62 (2024)
Cardiovascular (CV) diseases are the leading causes of death worldwide in both sexes alike. However, there have been significant developments in CV pharmacotherapy, percutaneous intervention, and systems of care over the past three decades in paralle
Externí odkaz:
https://doaj.org/article/5392e00ab70e4dffb71b252fa45914c7
Publikováno v:
European Pharmaceutical Journal, Vol 71, Iss 1, Pp 43-52 (2024)
While many types of diabetes medications are currently available, orally administered formulations of glucagon-like peptide-1 (GLP-1) receptor agonists have recently been launched. Therefore, gastrointestinal epithelial cells will be increasingly exp
Externí odkaz:
https://doaj.org/article/488d8589ad5b4523b9487db4bd9b345d
Autor:
Kevin Y. Heo, BS, Rahul K. Goel, MD, Andrew Fuqua, BS, Jeffrey S. Holmes, MD, Brian T. Muffly, MD, Greg A. Erens, MD, Jacob M. Wilson, MD, Ajay Premkumar, MD, MPH
Publikováno v:
Arthroplasty Today, Vol 30, Iss , Pp 101506- (2024)
Background: Glucagon-like peptide-1 (GLP-1) agonists have emerged as a powerful diabetic treatment adjunct; however, its effects on outcomes following total knee arthroplasty (TKA) are not well known. The purpose of this study was to compare the risk
Externí odkaz:
https://doaj.org/article/72431e2db9dc44a98beba3263a2de5e0
Publikováno v:
Frontiers in Clinical Diabetes and Healthcare, Vol 5 (2024)
Externí odkaz:
https://doaj.org/article/c8f20dba13b54f4a9494c9824b74d410
Autor:
Xiaoling Cai, Linong Ji, Mingxia Yuan, Jianhua Ma, Fang Bian, Sheli Li, Wuyan Pang, Shuang Yan, Huimin Zhou, Minghui Hou, Wenhui Li, Ying Jia, Li Liu, Ke Ding, Michael Xu
Publikováno v:
The Lancet Regional Health. Western Pacific, Vol 51, Iss , Pp 101197- (2024)
Summary: Background: Visepegenatide, a once-weekly glucagon-like peptide-1 receptor agonist injection, demonstrated effective glycaemic control and good tolerability without the requirement of dose titration in the two completed phase 2 studies. We a
Externí odkaz:
https://doaj.org/article/41923e3bab6b46929eafd3806d8a14b0
Autor:
Taher Modarressi
Publikováno v:
American Journal of Preventive Cardiology, Vol 19, Iss , Pp 100706- (2024)
Background: Lipid-related risk and residual cardiovascular risk remain high in patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD). Significant treatment gaps exist in implementation of pluripotent and effective the
Externí odkaz:
https://doaj.org/article/25893c841e63492f9957115178d9a9d8
Autor:
Angelina Lęgas, Joanna Smalira, Bartosz Przybysz, Jakub Kawalec, Julia Zawistowska, Karolina Rogowska, Katarzyna Pochodowicz, Weronika Rogala, Weronika Rutkowska-Kawalec, Karolina Urbańska
Publikováno v:
Quality in Sport, Vol 22 (2024)
Introduction and objective Obesity poses a significant public health challenge due to its association with an elevated risk of various chronic diseases, including cardiovascular conditions, type 2 diabetes, and overall mortality. While lifestyle mod
Externí odkaz:
https://doaj.org/article/6edfc145e2bd423a95a612312ad2fff7
Autor:
Sohail Bade, Sahil Bade, Grishma Sharma, Narayan Bhurtel, Yadvinder Singh, Sudip Paudel, Frena Pulami Magar, Kshitij Chapagain
Publikováno v:
Clinical Case Reports, Vol 12, Iss 9, Pp n/a-n/a (2024)
Key Clinical Message Dulaglutide is a relatively unpopular GLP‐1 receptor agonist used for weight loss. This case demonstrates that dulaglutide may be beneficial for weight loss in morbidly obese patients with multiple comorbidities after thoroughl
Externí odkaz:
https://doaj.org/article/ab451b4fed2840d8816f9b7661b902c4